Response of refractory colitis to intravenous or oral tacrolimus (FK506)

Inflammatory Bowel Diseases

Volumn 8, Issue 5, 2002, Pages 317-324

  Fellermann, Klaus ^a   Tanko, Zita ^b   Herrlinger, Klaus R ^a   Witthoeft, Thomas ^b   Homann, Nils ^b   Bruening, Andreas ^b   Ludwig, Diether ^b   Stange, Eduard F ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Cyclosporine; Immunosuppression; Refractory disease; Tacrolimus; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BECLOMETASONE; CALCIUM; CIPROFLOXACIN; CYCLOSPORIN A; ENEMA; INSULIN; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PURINE DERIVATIVE; STEROID; TACROLIMUS; VITAMIN D;

ACNE; ADULT; AFFECTIVE NEUROSIS; ALOPECIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; COLON RESECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRICHOSIS; INFECTION; KIDNEY DYSFUNCTION; LABORATORY TEST; LEUKOPENIA; MALE; MUSCLE CRAMP; NAUSEA AND VOMITING; NOCTURIA; OSTEOPENIA; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; REMISSION; SURVIVAL RATE; TREATMENT OUTCOME; TREMOR; VISUAL IMPAIRMENT;

EID: 0036743048     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200209000-00002     Document Type: Article

References (34)

1. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-15.
2. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423-8.
3. Woodle ES, Thistlethwaite JR, Gordon JH, et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplant 1996;62:594-9.
4. Knoll GA, Bell RC. Tacrolimus versus cyclosporine for immunosuppression in renal transplantation: meta-analysis of randomised trials. Br Med J 1999;318:1104-7.
5. Klein A. Tacrolimus rescue in liver transplant patients with refractory rejection or intolerance or malabsorption of cyclosporine. The US multicenter FK506 Liver Study Group. Liver Transpl Surg 1999;5: 502-8.
6. Bierer BE. Biology of cyclosporine A and FK506. Prog Clin Biol Res 1994;390:203-23.
7. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841-5.
8. Carbonnel F, Boruchowicz A, Duclos B, et al. Intravenous cyclosporine in attacks of ulcerative colitis. Dig Dis Sci 1996;41: 2471-6.
9. Travis SPL, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10.
10. Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol 1998;10:411-13.
11. Fernandez-Banares F, Bertran X, Esteve-Comas M, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996;91:2498-9.
12. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94:1587-92.
13. Santos J, Baudet S, Casellas F, et al. Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis. J Clin Gastroenterol 1995;20:285-9.
14. Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus. Am J Gastroenterol 1998;93:1860-6.
15. Peters DH, Fitton A, Plosker GL, et al. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46:746-94.
16. Lowry PW, Weaver AL, Tremaine WJ, et al. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis 1999;5:239-45.
17. Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000;137:794-9.
18. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997;337: 816-21.
19. Van Thiel DH, Carroll PB, Abu-Elmagd K, et al. Tacrolimus (FK506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90:455-9.
20. Stephens J, Goldstein R, Crippin J, et al. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. Transplant Proc 1993;25:1122-3.
21. Bousvaros A, Leichtner AM, Book L, et al. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). Gastroenterology 1996;111:237-43.
22. Aiko S, Conner EM, Fuseler JA, et al. Effects of cyclosporine or FK506 in chronic colitis. J Pharmacol Exp Ther 1997;280: 1075-84.
23. Price AB. Overlap in the spectrum of non-specific inflammatory bowel disease-"colitis indeterminate." J Clin Pathol 1978;31: 567-77.
24. George J, Present DH, Pou R, et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996;91:1711-14.
25. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J 1982;284:1291-2.
26. Orth T, Peters M, Schlaak JF, et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000;95:1201-7.
27. Fellermann K, Steffen M, Stein J, et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:171-6.
28. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955;2:1041-8.
29. Boesken WH. Diagnostic significance of SDS-PAA-electrophoresis of urinary proteins: different forms of proteinuria and their correlation to renal diseases. Curr Probl Clin Biochem 1979;235-48.
30. Sandborn WJ, Tremaine WJ, Lawson GM. Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine. Am J Gastroenterol 1996;91:37-43.
31. Herrlinger KR, Noftz MK, Fellermann K, et al. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther 2001;15: 363-9.
32. Ierardi E, Principi M, Rendina M, et al. Oral tacrolimus (FK506) in Crohn's disease complicated by fistulae of the perineum. J Clin Gastroenterol 2000;30:200-2.
33. Casson DH, Eltumi M, Tomlin S, et al. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000;47:436-40.
34. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy of severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-9.